How We Can Use the FDA’s 2022 Diversity Guidance to Make Our Clinical Trials More Inclusive
Executive Summary
Catherine Gregor is the chief clinical trial officer at Florence Healthcare, a leading provider of clinical trial software that helps researchers collaborate and manage workflows and information. Based on her extensive experience in clinical research administration, Gregor explains how the recent US FDA guidance on diversity and inclusion in clinical trials represents a critical opportunity to make clinical research more inclusive and equitable.
You may also be interested in...
US Senators Press CMS To Expand Coverage Of Dementia Diagnostic Scan
US Senators sent a letter to CMS and HHS urging the expansion of amyloid PET scan coverage.
Racial And Ethnic Diversity In Clinical Trials: A Social And Scientific Imperative
From new FDA guidance and community engagement efforts to the challenges of precision medicine and decentralization, In Vivo spoke with industry experts about racial and ethnic diversity in the context of clinical trials.
Clinical Trial Diversity Campaign Distracting From Health Equity Problems, Califf Says
The FDA commissioner says that improving health disparities would fix the lack of diversity in clinical trials.